Subscribe To
NVTA / Invitae Corp (NVTA) CEO Kenneth Knight on Q2 2022 Results - Earnings Call Transcript
NVTA News
By The Motley Fool
November 4, 2023
3 Things About Invitae Every Smart Investor Knows
Invitae's stock is down and it might get delisted from its stock exchange. It has a new crop of top managers, but it's running low on cash. more_horizontal
By The Motley Fool
November 1, 2023
Is Invitae Stock a Buy Now?
Invitae's revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into pro more_horizontal
By The Motley Fool
October 2, 2023
Why Invitae Stock Popped Today
Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind more_horizontal
By InvestorPlace
October 2, 2023
Why Is Invitae (NVTA) Stock Up 28% Today?
Invitae (NYSE: NVTA ) stock is on the rise Monday despite a lack of news from the medical genetics company this morning. There haven't been any new pr more_horizontal
By The Motley Fool
September 14, 2023
Cathie Wood Is Betting on This Struggling Stock. Should You?
Invitae has struggled to turn rising revenue into profit. Last year, the company launched a strategic plan to pave the way to positive cash flow and i more_horizontal
By The Motley Fool
July 26, 2023
Down 97%, Is It Finally Time to Buy Invitae Stock?
Stock market analysts have conflicting opinions about the market value of this genetic testing business. Worth more than $10 billion at its peak, beat more_horizontal
By Zacks Investment Research
July 21, 2023
Invitae (NVTA) Upgraded to Buy: Here's Why
Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal
By The Motley Fool
July 12, 2023
Down 98% Is This Cathie Wood Stock a Screaming Buy?
Popular investment manager Cathie Wood is known for investing in innovative growth stocks. more_horizontal